Hark, gentle reader, and attend to the chronicle of a remarkable innovation: The Breakthrough DDS Technology.

Krisulin's DDS platform doth combine a multitude of technologies, conceived to enhance the oral absorption and bioavailability of endogenous peptides in a stable fashion. Verily, this stands as the very first such innovation in the annals of science and commerce.

Historically, the high dosage requirements for oral analog peptides have rendered their scaling a difficult affair, thereby favouring the development of small-molecule alternatives for the reduction of corpulence. Moreover, the nascent data from even the newest platforms (presently bearing INN nomenclature) doth suggest a reduced efficacy and a more frequent onset of untoward effects when set beside peptides.

Neither other existing platforms, which were designed to surmount these selfsame challenges, have yet enabled the effective oral administration of analog peptides at doses potentially significantly lower than those of other oral peptides currently in development.

The Krisulin DDS platform, suitable for both oral administration and injection, doth cater to APIs both great and small (including, but not restricted to, mAbs, vaccines, proteins, mRNA, and endogenous peptides such as GLP-1, GIT, and insulin). It maketh no use of any manner of artificial enhancer, neither for transport, absorption, nor for the stability of the transported API, and doth not moderate endogenous APIs.

This platform, therefore, constitutes a first—and not-too-much-ado-about—breakthrough in the methods of transport for molecules great and small, in nanobiotechnology, DNA/RNA techniques, the development of polyclonal products, and many other strategic areas of healthcare.

Most revolutionary is the singular, world-exclusive plausibility of this DDS to deliver orally ENDOGENOUS peptides and unmodified large molecules, boasting a bioavailability in animal studies that doth cross the barrier of 50% to 90%. This, excluding cyclosporine (and its derivatives or similar cyclic compounds), is truly a BiC (Best in Class) and a FiC (First in Class) achievement.

Add to this a DDS chemical structure that is wholly biocompatible (GRAS), and one finds oneself, metaphorically speaking, in the very air of the Holy Spirit.

With high probability with Krisulin:

• No longer injectable vaccines are needed, as DDS orally delivers any of them to the systemic (or lymphatic) system only.
• and no more non-selective antibiotics are needed, by the same token.
• No longer highly inefficient LNP m-RNA vaccines are needed (due to 99% efficient endosomal escape of the DDS).
• No longer threats about antitumour therapies are needed (amid applications of DDS to PDA and PDD).